Physician profile
Elcin Zan
NPI 1639441215
$30,272.67
in general payments reported to CMS, 2019-2025
11 companies · $15K in 2025
The $15K reported for 2025 was more than what 97% of Nuclear Imaging & Therapy providers received nationally (typical 2025 total: $122).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,076 · 2020: $5,337 · 2022: $45.42 · 2023: $151 · 2024: $4,096 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $4,865 · Food and Beverage: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,605.00 |
| Travel and Lodging | $4,864.83 |
| Food and Beverage | $1,344.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,988.58 | 2023-2025 | |
| Siemens Medical Solutions USA, INC. | $7,967.91 | 2019-2025 | Symbia Pro.Specta Q3, Biograph Trinion Ep Ct64, Symbia Pro.Specta X7 |
| Advanced Accelerator Applications | $5,955.84 | 2019 | |
| Genentech, INC. | $4,197.04 | 2025 | |
| Astrazeneca Uk Limited | $1,860.00 | 2025 | |
| Curium US LLC | $1,736.55 | 2024 | |
| Telix Pharmaceuticals | $176.91 | 2025 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $153.75 | 2023-2024 | Lynparza |
| Ge Healthcare | $126.43 | 2024 | |
| Canon Healthcare USA, INC. | $85.52 | 2025 | |
| Blue Earth Diagnostics | $24.14 | 2025 | Posluma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elcin Zan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.